#Eli Lilly
articles
Eli Lilly's Foundayo Launch Puts UK Brokers on Counterfeit and Disclosure Watch
The UK debut of Eli Lilly's daily Foundayo pill could widen non-disclosure in life, travel and private medical insurance...
Eli Lilly's Foundayo Launch Puts UK Brokers on Counterfeit and Disclosure Watch
The UK debut of Eli Lilly's daily Foundayo pill could widen non-disclosure in life, travel and private medical insurance...
Diabetes Treatment Is a $966 Billion Global Market Led by Novo Nordisk, Eli Lilly and Sanofi
Nearly 537 million people live with diabetes, and global health spending reached an estimated $966 billion in 2021. Here...
Eli Lilly’s Revenue Remains Overwhelmingly Tied to Endocrinology
With 74% of sales coming from endocrinology, the US drugmaking giant’s fortunes hinge on diabetes and obesity therapies....
Lilly's WNBA Campaign with Candace Parker Deepens Pharma's Bet on Women's Sports
Eli Lilly's new Amazon Prime ad starring Candace Parker signals a strategic shift—embedding health messaging into the bo...
Diabetes Market Surges Past $966 Billion as Patient Count Tops 537 Million
Global diabetes spending reached nearly $966 billion in 2021, driven by a disease burden affecting 10% of the world's po...
Eli Lilly's GLP-1 Juggernaut Powers 48% Revenue Jump, Eyes Next Obesity Blockbuster
Quarterly sales topped $23 billion as Mounjaro and Zepbound dominate the obesity drug market. With a new oral pill and a...
ADA Review, Retatrutide Access and GLP-1 Generics Lead a Busy Diabetes Week
A busy week for diabetes and obesity drugs: ADA reviews a police incident, Lilly expands retatrutide access, Novo faces ...
Eli Lilly's Mounjaro Hits R$13.5 Billion in First Year in Brazil, Reshaping Obesity Drug Market
Demand for tirzepatide outstripped expectations, boosting the Brazilian unit into Eli Lilly's global top 10, but looming...
Novo Nordisk Must Face Shareholder Fraud Claims Over CagriSema Disappointment
A U.S. judge ruled that Novo Nordisk must answer investor fraud allegations after the obesity drug trial missed its weig...
Novo Nordisk Sues Eli Lilly for ‘Deceptive’ Ads Using Outdated Dosing Data
Novo Nordisk alleges Eli Lilly compared its drugs to lower, non-current doses of Wegovy and Ozempic in advertising, seek...
Novo Nordisk Sues Eli Lilly Over ‘Unfair’ Comparison of Weight-Loss Drugs
The Danish drugmaker claims Eli Lilly’s advertising for Zepbound and Mounjaro used outdated Wegovy doses, misleading pat...